Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen
Public ClinicalTrials.gov record NCT01587040. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
International, Multicenter, Open-label, Treatment-extension Study for Subjects Who Completed a Phase 1 or Phase 2 Parental Study to Continue Receiving Treatment With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen
Study identification
- NCT ID
- NCT01587040
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Sanofi
- Industry
- Enrollment
- 61 participants
Conditions and interventions
Conditions
Interventions
- SAR245408 Drug
- SAR245409 Drug
Drug
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 19, 2012
- Primary completion
- May 22, 2018
- Completion
- May 22, 2018
- Last update posted
- Apr 18, 2022
2012 – 2018
United States locations
- U.S. sites
- 16
- U.S. states
- 13
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site Number 840010 | Birmingham | Alabama | 35205 | — |
| Investigational Site Number 840009 | Los Angeles | California | 90024 | — |
| Investigational Site Number 840008 | Los Angeles | California | 90033 | — |
| Investigational Site Number 840022 | Denver | Colorado | 80262 | — |
| Investigational Site Number 840104 | Fort Myers | Florida | 33919 | — |
| Investigational Site Number 840006 | Augusta | Georgia | 30912 | — |
| Investigational Site Number 840004 | Boston | Massachusetts | 02115 | — |
| Investigational Site Number 840021 | St Louis | Missouri | 63110 | — |
| Investigational Site Number 840002 | New Brunswick | New Jersey | 08903 | — |
| Investigational Site Number 840020 | Canton | Ohio | 44718 | — |
| Investigational Site Number 840015 | Columbus | Ohio | 43210 | — |
| Investigational Site Number 840017 | Philadelphia | Pennsylvania | 19111 | — |
| Investigational Site Number 840007 | Nashville | Tennessee | 37232 | — |
| Investigational Site Number 840003 | Dallas | Texas | 75230 | — |
| Investigational Site Number 840005 | San Antonio | Texas | 78229 | — |
| Investigational Site Number 840018 | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01587040, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 18, 2022 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01587040 live on ClinicalTrials.gov.